Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer – implications for future research - Top-Institutions - MDSpire

Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer – implications for future research

  • By

  • Zeta Chow

  • Ronald Charles McGarry

  • Jordan Miller

  • Waleed Fouad Mourad

  • Ralph Zinner

  • Bernard Mark Evers

  • Weisi Yan

  • May 28, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Radiation Oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Radiation Oncology

  • #3

    City of Hope Comprehensive Cancer Center
    City of Hope Comprehensive Cancer Center

    Duarte, California

    Key Differentiators

    • Oncology
    • Radiation Oncology

  • #4

    UCLA Cardiovascular Center
    UCLA Cardiovascular Center

    Los Angeles, California

    Key Differentiators

    • Oncology
    • Cardiology

  • #5

    University of Michigan
    University of Michigan

    Ann Arbor, Michigan

    Key Differentiators

    • Oncology
    • Radiation Oncology

Original Source(s)

Understanding cardiac toxicity and immune responses to thoracic radiation therapy in non-small cell lung cancer – implications for future research

  • by Zeta Chow, Ronald Charles McGarry, Jordan Miller, Waleed Fouad Mourad, Ralph Zinner, Bernard Mark Evers, Weisi Yan

  • May 28, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer